3 Items


Tech and Public Policy to Save the Brain

  • Priyamvada Saraf
  • Mathew Alexander
  • Sohaib Nasim
  • Hardy Ding
| May 03, 2023

Neurodegenerative diseases (NDDs) represent a global health emergency, affecting millions of individuals and imposing significant economic burdens. Despite increased funding and government initiatives, effective therapies remain elusive, and NDD research lags behind other fields. This report argues for a simplified, accelerated, and transparent unified approach to NDD research, building on lessons from other fields and industries.

teaser image

Blog Post - perspectives-on-public-purpose

Basic Science Research as the Pillar for NDD Drug Development

| Mar. 24, 2023

In the last decade, there has been a significant increase in the prevalence of neurodegenerative diseases (NDD) in the United States, affecting approximately 10.5 million individuals. This number is predicted to triple in the next 30 years.1 However, in comparison to other disease areas such as oncology, the approval of NDD drugs has been relatively limited. Our team has explored the NDD drug development ecosystem from three perspectives: stakeholders, funding, and policy. This article summarizes our key findings and presents a case study to suggest that the scarcity of new drug development may be attributable to insufficient basic scientific research. Finally, we outline our objectives for the upcoming semester.

teaser image

Blog Post - perspectives-on-public-purpose

Understanding How Policy Affects Neurodegenerative Disease Drug Development

| Dec. 16, 2022

As highlighted in our initial blog post, the neurodegenerative disease (NDD) drug development space has seen little progress compared to other disease areas such as cancer and immunology. A number of factors contribute to a lack of curative or disease-altering therapies addressing NDD including a poor understanding of the pathophysiology of most NDDs and historically lower investment as opposed to other disease areas. However, the use of policy instruments has the potential to drive progress and improve NDD drug development. This article introduces our research on the impact of key policies on NDD drug development. It also presents our initial findings on the effectiveness of current policies and identifies areas where further action is needed.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem